Literature DB >> 21883804

Intranasal administration of insulin to the brain impacts cognitive function and peripheral metabolism.

V Ott1, C Benedict, B Schultes, J Born, M Hallschmid.   

Abstract

In recent years, the central nervous system (CNS) has emerged as a principal site of insulin action. This notion is supported by studies in animals relying on intracerebroventricular insulin infusion and by experiments in humans that make use of the intranasal pathway of insulin administration to the brain. Employing neurobehavioural and metabolic measurements as well as functional imaging techniques, these studies have provided insight into a broad range of central and peripheral effects of brain insulin. The present review focuses on CNS effects of insulin administered via the intranasal route on cognition, in particular memory function, and whole-body energy homeostasis including glucose metabolism. Furthermore, evidence is reviewed that suggests a pathophysiological role of impaired brain insulin signaling in obesity and type 2 diabetes, which are hallmarked by peripheral and possibly central nervous insulin resistance, as well as in conditions such as Alzheimer's disease where CNS insulin resistance might contribute to cognitive dysfunction.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21883804     DOI: 10.1111/j.1463-1326.2011.01490.x

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN: 1462-8902            Impact factor:   6.577


  39 in total

Review 1.  Impaired insulin action in the human brain: causes and metabolic consequences.

Authors:  Martin Heni; Stephanie Kullmann; Hubert Preissl; Andreas Fritsche; Hans-Ulrich Häring
Journal:  Nat Rev Endocrinol       Date:  2015-10-13       Impact factor: 43.330

2.  Alfalfa-derived HSP70 administered intranasally improves insulin sensitivity in mice.

Authors:  Michael Tytell; Ashley T Davis; Jareca Giles; Lauren C Snider; Ruoyu Xiao; Stephen G Dozier; Tennille D Presley; Kylie Kavanagh
Journal:  Cell Stress Chaperones       Date:  2017-08-18       Impact factor: 3.667

Review 3.  Relationships between diabetes and cognitive impairment.

Authors:  Suzanne M de la Monte
Journal:  Endocrinol Metab Clin North Am       Date:  2013-12-12       Impact factor: 4.741

Review 4.  Intranasal insulin therapy for cognitive impairment and neurodegeneration: current state of the art.

Authors:  Suzanne M de la Monte
Journal:  Expert Opin Drug Deliv       Date:  2013-11-12       Impact factor: 6.648

Review 5.  Alzheimer's disease and insulin resistance: translating basic science into clinical applications.

Authors:  Fernanda G De Felice
Journal:  J Clin Invest       Date:  2013-02-01       Impact factor: 14.808

6.  Zinc and the aging brain.

Authors:  Johnathan R Nuttall; Patricia I Oteiza
Journal:  Genes Nutr       Date:  2013-12-24       Impact factor: 5.523

7.  Intranasal insulin suppresses systemic but not subcutaneous lipolysis in healthy humans.

Authors:  K Alexander Iwen; Thomas Scherer; Martin Heni; Friedhelm Sayk; Toni Wellnitz; Felix Machleidt; Hubert Preissl; Hans-Ulrich Häring; Andreas Fritsche; Hendrik Lehnert; Christoph Buettner; Manfred Hallschmid
Journal:  J Clin Endocrinol Metab       Date:  2013-01-01       Impact factor: 5.958

8.  Dietary glycaemic load associated with cognitive performance in elderly subjects.

Authors:  Susan E Power; Eibhlís M O'Connor; R Paul Ross; Catherine Stanton; Paul W O'Toole; Gerald F Fitzgerald; Ian B Jeffery
Journal:  Eur J Nutr       Date:  2014-07-18       Impact factor: 5.614

Review 9.  [Targeting the brain through the nose. Effects of intranasally administered insulin].

Authors:  Y F Brünner; C Benedict; J Freiherr
Journal:  Nervenarzt       Date:  2013-08       Impact factor: 1.214

10.  Intranasal Cotinine Plus Krill Oil Facilitates Fear Extinction, Decreases Depressive-Like Behavior, and Increases Hippocampal Calcineurin A Levels in Mice.

Authors:  Nathalie Alvarez-Ricartes; Patricia Oliveros-Matus; Cristhian Mendoza; Nelson Perez-Urrutia; Florencia Echeverria; Alexandre Iarkov; George E Barreto; Valentina Echeverria
Journal:  Mol Neurobiol       Date:  2018-02-27       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.